Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma
Name:
37319435.pdf
Size:
412.5Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Armand, P.Zinzani, P. L.
Lee, H. J.
Johnson, N. A.
Brice, P.
Radford, John A
Ribrag, V.
Molin, D.
Vassilakopoulos, T. P.
Tomita, A.
von Tresckow, B.
Shipp, M. A.
Herrera, A. F.
Lin, J.
Kim, E.
Chakraborty, S.
Marinello, P.
Moskowitz, C. H.
Affiliation
Dana-Farber Cancer Institute, Boston, Massachusetts, United StatesIssue Date
2023
Metadata
Show full item recordAbstract
Previous analyses from the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), but longer-term response durability and outcome of patients who receive a second course after treatment discontinuation after complete response (CR) remain of clinical interest. We present KEYNOTE-087 data after >5 years of median follow-up. Patients with R/R cHL and progressive disease (PD) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV; cohort 1); after salvage chemotherapy and BV without ASCT (cohort 2); or after ASCT without subsequent BV (cohort 3) received pembrolizumab for ≤2 years. Patients in CR who discontinued treatment and subsequently experienced PD were eligible for second-course pembrolizumab. Primary end points were objective response rate (ORR) by blinded central review and safety. Median follow-up was 63.7 months. ORR was 71.4% (95% confidence interval [CI], 64.8-77.4; CR, 27.6%; partial response, 43.8%). Median duration of response (DOR) was 16.6 months; median progression-free survival was 13.7 months. A quarter of responders, including half of complete responders, maintained response ≥4 years. Median overall survival was not reached. Among 20 patients receiving second-course pembrolizumab, ORR for 19 evaluable patients was 73.7% (95% CI, 48.8-90.8); median DOR was 15.2 months. Any-grade treatment-related adverse events occurred in 72.9% of patients and grade 3 or 4 in 12.9%; no treatment-related deaths occurred. Single-agent pembrolizumab can induce very durable responses, especially in patients achieving CR. Second-course pembrolizumab frequently reinduced sustained responses after relapse from initial CR.Citation
Armand P, Zinzani PL, Lee HJ, Johnson NA, Brice P, Radford J, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma. Blood. 2023 Jun 15. PubMed PMID: 37319435. Epub 2023/06/15. eng.Journal
BloodDOI
10.1182/blood.2022019386PubMed ID
37319435Additional Links
https://dx.doi.org/10.1182/blood.2022019386Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood.2022019386